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Purpose: To quantify retinal nerve fiber layer (RNFL) changes in patients with multiple sclerosis (MS) and
healthy controls with a 5-year follow-up and to analyze correlations between disability progression and RNFL
degeneration.
Design: Observational and longitudinal study.
Participants: One hundred patients with relapsing-remitting MS and 50 healthy controls.
Methods: All participants underwent a complete ophthalmic and electrophysiologic exploration and were
re-evaluated annually for 5 years.
Main Outcome Measures: Visual acuity (Snellen chart), color vision (Ishihara pseudoisochromatic plates),
visual field examination, optical coherence tomography (OCT), scanning laser polarimetry (SLP), and visual
evoked potentials. Expanded Disability Status Scale (EDSS) scores, disease duration, treatments, prior optic
neuritis episodes, and quality of life (QOL; based on the 54-item Multiple Sclerosis Quality of Life Scale score).
Results: Optical coherence tomography (OCT) revealed changes in all RNFL thicknesses in both groups. In
the MS group, changes were detected in average thickness and in the mean deviation using the GDx-VCC nerve
fiber analyzer (Laser Diagnostic Technologies, San Diego, CA) and in the P100 latency of visual evoked potentials;
no changes were detected in visual acuity, color vision, or visual fields. Optical coherence tomography showed
greater differences in the inferior and temporal RNFL thicknesses in both groups. In MS patients only, OCT
revealed a moderate correlation between the increase in EDSS and temporal and superior RNFL thinning.
Temporal RNFL thinning based on OCT results was correlated moderately with decreased QOL.
Conclusions: Multiple sclerosis patients exhibit a progressive axonal loss in the optic nerve fiber layer.
Retinal nerve fiber layer thinning based on OCT results is a useful marker for assessing MS progression and
correlates with increased disability and reduced QOL. Ophthalmology 2017;-:1e9 ª 2017 by the American
Academy of Ophthalmology.The main cause of disability in patients with multiple
sclerosis (MS) is axonal loss.1e3 Axonal deterioration in the
retinal nerve fiber layer (RNFL) can be detected and
quantified using optical coherence tomography (OCT) or
scanning laser polarimetry (SLP).3e8 Typical ophthalmic
findings in MS patients are optic nerve atrophy and peri-
papillary RNFL thinning.8
The effects of MS on the central nervous system gener-
ally are difficult to examine directly, but the RNFL, which is
made up of mainly nonmyelinated retinal ganglion cell
axons, provides easy access for clinical examination. The
RNFL thickness can be measured to assess axons and
axonal damage directly. Even in MS patients without pre-
ceding symptoms of optic neuritis show decreases in RNFL
thickness.4e8 Visual evoked potential (VEP) tests also
reveal abnormalities in MS patients.9e11
Optical coherence tomography has been used to
measure RNFL thickness as a biologic marker of axonal
damage12e14 and to monitor disease progression in patientsª 2017 by the American Academy of Ophthalmology
Published by Elsevier Inc.with MS.7,8 In fact, some authors suggest that OCT may be
an efficient and less expensive substitute for magnetic
resonance imaging as a method of monitoring the
disease.15e17 In this study, we compared structural and
functional changes in the RNFL in MS patients with those in
healthy controls. We further evaluated the correlation of the
RNFL changes with disease progression and changes in
quality of life (QOL) over 5 years.Methods
Participants
This prospective longitudinal study included patients with definite
relapsing-remitting MS and healthy controls with a 5-year follow-
up. A total of 204 eyes of 102 patients and 100 eyes of 50 healthy
controls were evaluated at baseline and then every year for 5 years.
Multiple sclerosis was diagnosed based on the 2010 revision of the
McDonald criteria and confirmed by a neurologist specializing in1http://dx.doi.org/10.1016/j.ophtha.2017.01.005
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Ophthalmology Volume -, Number -, Month 2017MS.18 Patients with a visual acuity less than 0.1 (Snellen scale),
intraocular pressure more than 20 mmHg, active MS flare (of
any neurologic deficit), or a combination thereof in the 6 months
preceding their enrollment into the study or at any of the annual
visits were excluded from the study. Active MS flare was
considered a reason for exclusion because acute axonal loss
could mask neuronal damage secondary to MS progression (i.e.,
chronic neurodegeneration), which was the main purpose of this
study. Patients with refractive errors of more than 5 diopters of
spherical equivalent refraction or 3 diopters of astigmatism also
were excluded from the study.
Standard Protocol Approvals, Registrations, and
Patient Consents
The study procedures were performed in accordance with the tenets
of the Declaration of Helsinki, and the study protocol was
approved by the local ethics committees. Written informed consent
to participate in the study was obtained from all participants.
Main Outcome Measures
All participants underwent a complete neuro-ophthalmic exami-
nation, including assessment of best-corrected visual acuity
using the Snellen chart, pupillary reflexes, and ocular motility;
examinations of the anterior segment, intraocular pressure (IOP)
with the Goldmann applanation tonometer, and papillary
morphologic features by funduscopic examination; and OCT, SLP,
and VEP. Each eye was considered separately. In addition, the
Expanded Disability Status Scale (EDSS) score, disease duration,
treatments, prior episodes of optic neuritis, and QOL (using the
54-item Multiple Sclerosis Quality of Life Scale [MSQOL-54]
score) were evaluated. Every year for 5 years, patients were re-
examined and changes in all parameters were recorded. An in-
crease in the EDSS score during the follow-up was considered a
sign of disease progression.
Visual acuity was measured with the Snellen chart at a distance
of 6 m and best-corrected monocular vision. The papilla morpho-
logic features were assessed with a 78-diopter lens and classified as
normal, diffuse, or sectorial atrophy or edema.
Peripapillary RNFL and macular volume measurements were
obtained using the Cirrus 3000 HD OCT (Carl Zeiss Meditec, Jena,Table 1. Epidemiologic and Neurologic Parameters Obtained at Basel
Healthy C
Multiple Sclerosis Patients (n
Basal Exploration 5-Ye
Age (yrs) 41.12 (11.45) 46
Gender (female:male) 68:32
Intraocular pressure (mmHg) 14.26
MS disease duration (yrs) 9.26 (6.68) 14
EDSS score 2.59 (2.13) 2
EDSS visual function score 1.00 (1.20) 0
MSQOL-54 score 60.04 (21.55) 56
Eyes with history of ON, n (%) 51 (25.5)
Time since last ON episode (yrs) 7.74 (6.28) 12
EDSS ¼ Expanded Disability Status Scale; MS ¼ multiple sclerosis; MSQOL-5
Boldface values indicate a statistically significant difference.
Data are mean (standard deviation) unless otherwise indicated.
*Multiple sclerosis patients versus controls.
yMultiple sclerosis patients versus multiple sclerosis patients at 5 years.
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Germany). The same experienced operator (E.V.) performed all
scans, and no manual correction was applied to the OCT output.
An internal fixation target was used to ensure the highest repro-
ducibility, and poor-quality scans were rejected before analysis of
the data. For the Cirrus OCT scans, image quality was assessed
based on the signal strength measurement, which is a combination
of the signal-to-noise ratio and the uniformity of the signal within a
scan (scale of 1e10, where 1 is categorized as poor image quality
and 10 as excellent image quality). We analyzed only those images
with a score of more than 7. The Cirrus OCT optic disc protocol
generates 200200 cube images with 200 lineal scans that enable
analysis of a 6-mm3 area around the optic nerve, and the Cirrus
OCT macular cube 512128 protocol provides macular volume
measure. For each scan series, mean RNFL thickness, quadrant
RNFL thicknesses (superior, inferior, temporal, and nasal), and
macular volume were assessed using Cirrus software version 5.0.
Cirrus segmentation analysis for retinal layers also provides
measurements of ganglion cell layer (GCL) thickness (evaluating 6
areas of the macular cube: superior, superonasal, inferonasal,
inferior, inferotemporal, and superotemporal sectors) and mea-
surements of the mean and minimum GCL plus inner plexiform
layer value of a set of 360 spokes, where each average represents
the mean number of the pixels along the spoke that lies within the
measurement annulus. The minimum was selected because the
thinnest portion of the GCL plus inner plexiform layer in the
perifoveal region is considered to indicate the status of the ganglion
cells (the most important cells in the visual pathway).
The GDx-VCC (Laser Diagnostic Technologies, San Diego,
CA), consisting of a confocal scanning laser ophthalmoscope, was
used to determine RNFL thickness by directing polarized light onto
the Henle fiber layer and assessing 5 parameters: nerve fiber
indicator, temporalesuperiorenasaleinferioretemporal (TSNIT)
average, superior average, inferior average, and TSNIT standard
deviation.
Study investigators recorded VEPs, with electrodes fixed (with
collodion) at the midoccipital and midfrontal locations and Cz
(Z-center is the equidistant point between both ear points) as
ground, using a Neuronic SenseWitness 4.0 device (Neuronic,
Zaragoza, Spain) in a dark room and with full-refraction correction
if necessary. Monocular stimulation and visual stimuli followed a
checkerboard pattern (contrast, 80%; check size, 47 feet; mean
luminance, 93 cd/m2) and reversed contrast patterns with aine and 5-Year Examinations in Multiple Sclerosis Patients and in
ontrols
[ 100) Healthy Controls (n [ 50),
Basal Exploration P Valuear Exploration
.11 (11.40) 41.40 (13.33) 0.145*
68:32 35:15 0.223*
14.98 14.77 0.452*
.25 (6.67) d <0.001y
.65 (2.14) d 0.016y
.98 (1.15) d 0.098y
.76 (24.65) d 0.003y
51 (25.5) d 0.901y
.69 (6.98) d <0.001y
4 ¼ 54-item Multiple Sclerosis Quality of Life Scale; ON ¼ optic neuritis.
Garcia-Martin et al  Progressive Degeneration in MSfrequency of 1 Hz. Latency and peak-to-peak amplitude were
recorded for the P100 wave. We obtained at least 2 records of 100
events and calculated the mean amplitude.
The MSQOL-54 is a multidimensional health-related measure
of QOL that combines generic and MS-specific items into a single
instrument.19 This test is based on the 36-item Short Form Health
Survey, and 18 items were added by the test developer to assess
MS-specific issues, such as fatigue and cognitive function. The
resultant 54-item instrument generates 12 subscales along with
2 summary scores and 2 additional single-item measures. The
subscales are physical function, role limitationsephysical, role
limitationseemotional, pain, emotional well being, energy, health
perceptions, social function, cognitive function, health distress,
overall QOL, and sexual function. All dimension scores were
transformed linearly to a 0-to-100 scale. The summary scores are
the physical health composite summary and the mental health
composite summary; in addition, a global index score was
computed as the mean of the dimension scores. Single-item
measures are sexual satisfaction and change in health. The
MSQOL-54 is considered both valid and reliable and is accepted
widely to assess QOL accurately.19 The validity of the test also has
been confirmed in European patients,19 and it is currently the most
frequently used MS-specific questionnaire.19e21Table 2. Functional and Structural Parameters Obtained at Baseline and
Controls and Comparison of the Change in Each Group and between




BCVA 0.91 (0.22) 0.90 (0.19) 0.002 0.340
Ishihara test 18.06 (3.78) 17.89 (3.11) 0.034 0.439
Visual field, MD (dB) 3.05 (2.67) 3.11 (3.40) 0.012 0.441
OCT RNFL thicknesses
Average (mm) 94.82 (17.45) 86.61 (14.90) 1.642 <0.001*
Superior (mm) 115.95 (22.01) 104.34 (21.04) 2.322 <0.001*
Nasal (mm) 74.34 (18.99) 68.11 (14.33) 1.246 <0.001*
Inferior (mm) 120.89 (23.17) 111.34 (23.63) 1.910 <0.001*
Temporal (mm) 64.57 (19.67) 53.65 (13.13) 2.184 <0.001*
Macular volume (mm3) 6.55 (0.33) 6.43 (0.29) 0.024 <0.001*
OCT GCL analysis (mm)
Average IPLþGCL 78.45 (3.55) 74.89 (3.71) 0.712 <0.001*
Minimum IPLþGCL 79.09 (3.07) 77.55 (3.70) 0.308 0.209
Fovea 252.97 (7.49) 248.97 (8.87) 0.800 <0.001*
Inferior 80.73 (3.28) 78.16 (2.95) 0.514 0.011
Inferonasal 82.97 (3.98) 81.08 (4.06) 0.378 0.123
Nasal 84.73 (3.86) 81.01 (3.99) 0.744 <0.001*
Superior 80.95 (3.87) 77.49 (3.73) 0.692 0.007
Inferotemporal 78.81 (3.76) 74.33 (3.41) 0.896 <0.001*
Temporal 78.86 (3.60) 74.12 (4.00) 0.948 <0.001*
SLP (mm)
NFI 25.15 (8.53) 25.45 (8.09) 0.060 0.145
TSNIT average 51.87 (10.22) 50.87 (11.65) 0.020 0.045
Superior average 62.14 (12.43) 62.43 (11.19) 0.058 0.137
Inferior average 59.65 (9.48) 59.34 (11.50) 0.062 0.299
TSNIT SD 21.95 (5.03) 23.14 (5.44) 0.238 0.016
VEP
Amplitude (mV) 11.22 (2.71) 10.89 (3.33) 0.066 0.103
Latency (ms) 116.33 (10.21) 124.03 (11.02) 1.540 0.009*
BCVA ¼ best-corrected visual acuity; GCL ¼ ganglion cell layer; IPL ¼ inn
OCT ¼ optical coherence tomography; RNFL ¼ retinal nerve fiber layer; S
temporalesuperiorenasaleinferioretemporal; VEP ¼ visual evoked potential.
Data are mean (SD) unless otherwise indicated. P < 0.05 was considered to in
*Statistical significance using Bonferroni’s correction for multiple comparisons.Statistical Analysis
Data were analyzed using SPSS software version 20.0 (SPSS, Inc.,
Chicago, IL). The Kolmogorov-Smirnov test was used to assess
sample distribution. The changes registered in MS and healthy
participants over the 5-year study period were parametrically
distributed and thus compared using a paired Student t test.
Changes detected in the MS patients were compared with those
detected in healthy controls using a Student t test. Values of
P < 0.05 were considered to indicate statistical significance;
Bonferroni’s correction for multiple comparisons was applied and
a P value of less than 0.009 was considered statistically significant.
The linear correlation between changes in the structural and
functional parameters of the RNFL and changes in the MSQOL-54
or EDSS scores was determined using Pearson’s correlation
coefficient. Regression analysis was performed to identify basal
RNFL parameters that were predictors of QOL or reduced func-
tional ability in MS patients. Changes in the ophthalmologic
parameters, QOL, and disability parameters over the 5-year
follow-up were compared between patients with and without
prior optic neuritis using a Student t test and with healthy controls
by analysis of variance. Finally, following the Advised Protocol
for OCT Study Terminology and Elements recommendations for5-Year Examinations in Multiple Sclerosis Patients and in Healthy
Both Groups (Multiple Sclerosis Patients vs. Healthy Controls)






0.98 (0.04) 0.99 (0.02) 0.002 0.549 0.094
19.40 (2.81) 19.38 (2.74) 0.004 0.699 0.122
0.31 (1.41) 0.29 (1.31) 0.004 0.105 0.550
98.21 (10.50) 95.79 (9.53) 0.484 0.032 <0.001*
122.49 (16.93) 120.27 (14.93) 0.444 0.035 <0.001*
78.50 (21.76) 76.59 (10.70) 0.382 0.044 <0.001*
126.10 (18.36) 124.73 (17.94) 0.274 0.075 <0.001*
68.14 (9.82) 65.87 (9.56) 0.454 0.028 <0.001*
8.29 (0.44) 8.23 (0.55) 0.012 0.009* <0.001*
83.12 (3.20) 81.56 (3.43) 0.312 0.079 <0.001*
81.23 (3.69) 80.00 (3.11) 0.246 0.106 0.065
256.12 (7.98) 253.38 (8.21) 0.548 0.014 <0.001*
82.45 (3.33) 80.66 (2.98) 0.358 0.056 0.125
84.54 (4.34) 82.32 (3.45) 0.444 0.035 0.354
85.25 (4.21) 83.22 (3.87) 0.406 0.078 0.512
83.21 (3.66) 80.98 (3.27) 0.446 0.028 0.034
82.02 (3.41) 80.56 (3.70) 0.292 0.230 0.001*
81.11 (3.93) 79.82 (4.11) 0.258 0.177 0.003
18.70 (6.87) 19.04 (7.80) 0.068 0.349 0.975
52.33 (6.01) 52.61 (7.71) 0.056 0.451 0.623
65.32 (5.98) 64.87 (5.50) 0.090 0.559 0.458
65.00 (7.09) 64.76 (6.96) 0.048 0.683 0.872
20.03 (4.21) 20.61 (4.16) 0.116 0.078 0.055
14.54 (2.67) 14.49 (2.55) 0.010 0.449 0.088
102.03 (7.49) 101.89 (6.90) 0.028 0.618 0.014
er plexiform layer; MD ¼ mean deviation; NFI ¼ nerve fiber indicator;
D ¼ standard deviation; SLP ¼ scanning laser polarimetry; TSNIT ¼
dicate statistical significance.
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Ophthalmology Volume -, Number -, Month 2017reporting quantitative OCT studies,22 comparison of the change
registered during the 5-year follow-up between patients and
controls was repeated using the mean of eyes with nonoptic
neuritis in the MS group.Results
A total of 204 eyes of 102 MS patients (mean age, 41.1211.45
years) and 100 eyes of 50 healthy controls (mean age,
41.4013.33 years) were included in the study. The female-to-
male ratio was 3:1 in both groups (70 women and 32 men in the
MS group, and 35 women and 15 men in controls group). Age,
gender, and intraocular pressure were not significantly different
between groups (P ¼ 0.145, 0.223, and 0.452, respectively). Two
patients progressed from relapsing-remitting MS type to secondary
progressive type during the study, and the data for these patients
were excluded from the final statistical analysis.
The mean EDSS score was 2.592.13 at the baseline exami-
nation and 2.652.14 at the 5-year visit, with an annual change of
0.0120.003 (P ¼ 0.016). The MSQOL-54 score was
60.0421.55 at the baseline examination and 56.7624.65 at the
5-year visit, with an annual change of 0.650.21 (P ¼ 0.003).
Fifty-two (25.5%) of the MS eyes had had at least 1 optic neuritis
episode before beginning the study, and the mean time after these
episodes to the beginning of the study was 7.746.28 years. Age,
gender, intraocular pressure, EDSS score, MSQOL-54 score,
duration of disease, and time since last episode of optic neuritis are
shown in Table 1.
Interferon b-1b was the most frequently prescribed drug for MS
(21.3%) at the beginning of the study, followed by subcutaneous
interferon b-1a (15.7%), intramuscular interferon b-1a (11.4%),
and glatiramer acetate (10.1%). The percentage of patients not
receiving any treatment at the beginning of the study was 38.0%,
and that at the end of the follow-up was 37.6%. A total of 61
patients continued to receive their initially prescribed treatment
throughout the study.
Significant thinning of all parameters of the peripapillary
RNFL thickness and reduced macular volume based on OCT was
detected at the 5-year follow-up visit in both patients and controls
(except inferior RNFL thickness in healthy controls; Table 2).Figure 1. The mean retinal nerve fiber layer thickness measured by optical coh
mean P100 wave latency in visual evoked potentials (VEPs) in healthy control
group showed more thinning of the retinal nerve fiber layer thickness durin
temporalesuperiorenasaleinferioretemporal.
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Ganglion cell layer analysis of Cirrus OCT showed significant
thinning of all but 2 parameters in MS patients (minimum inner
plexiform layer plus GCL and inferotemporal quadrant). The
change in fovea, temporal, and inferotemporal measurements of
the GCL correlated significantly with the change in the EDSS
score over the 5-year follow-up (r ¼ 0.341 and P ¼ 0.047,
r ¼ 0.497 and P ¼ 0.009, and r ¼ 0.507 and P ¼ 0.002,
respectively).
Scanning laser polarimetry revealed a significant decrease in
TSNIT average and a significant increase in the TSNIT standard
deviation in the MS patient group, but these changes during the
follow-up did not differ significantly compared with those of
the healthy control group. A significant delay in the P100 wave
latency in VEP was observed in the MS group during the follow-up
and differed significantly from the control group throughout the
study (Table 2).
In the MS group, annual mean RNFL thickness measured by
OCT tended to decrease over the 5 years (Fig 1). The superior and
temporal RNFL thicknesses exhibited greater changes between
baseline and the 5-year follow-up in MS patients, with a
decrease in annual mean thickness of 2.32 mm (2.0%) and 2.18 mm
(3.4%), respectively (P < 0.001; Table 2; Fig 1).
Changes in the structural variables revealed by OCT and
SLP were not correlated significantly with changes in the
functional ophthalmologic variables over the 5-year follow-up
(best-corrected visual acuity, chromatic vision, visual field).
The change in the temporal and average RNFL sectors based on
OCT was moderately negatively correlated with the EDSS score
over the 5-year follow-up (r ¼ 0.426 and P ¼ 0.007, and
r ¼ 0.398 and P ¼ 0.010, respectively). In addition, the change
in the temporal RNFL sector based on OCT was correlated
moderately positively with the change in the MSQOL-54 score
over the 5-year follow-up (r ¼ 0.533 and P ¼ 0.031). The
change in SLP parameters was not correlated significantly with
the neurologic scale scores. The change in the inferior and
average RNFL sectors based on OCT was correlated moderately
with the change in the inferior and TSNIT averages of SLP over
the 5-year follow-up (r ¼ 0.701 and P ¼ 0.021, and r ¼ 0.742
and P ¼ 0.009, respectively).
Changes in the functional and structural parameters over the
5-year follow-up were compared between eyes with and without aerence tomography (OCT) and scanning laser polarimetry (SLP) and the
s and multiple sclerosis (MS) patients during 5 years of follow-up. The MS
g the follow-up and higher delays in the P100 wave latency. TSNIT ¼
Table 3. Functional and Structural Parameters Obtained at Baseline and 5-Year Examinations in Multiple Sclerosis Patients with and without Optic Neuritis Antecedent and
Comparisons of the Change in Each Group (Paired Student t test), between Both Groups (Multiple Sclerosis Patients with and without Optic Neuritis; Student t test), and between
Both Groups and Healthy Controls (Analysis of Variance)














Change P Value Baseline 5 Years
Annual
Change P Value
BCVA 0.86 (0.24) 0.85 (0.26) 0.002 0.650 0.96 (0.19) 0.95 (0.18) 0.002 0.700 0.602 0.539
Ishihara test 15.33 (4.75) 15.70 (4.19) 0.074 0.707 19.11 (2.34) 18.90 (2.49) 0.042 0.821 0.401 0.397
Visual field, MD (dB) 5.54 (3.98) 5.22 (4.31) 0.064 0.542 2.00 (2.11) 2.17 (2.67) 0.034 0.218 0.682 0.487
OCT RNFL thicknesses
Average (mm) 92.34 (18.68) 82.71 (16.71) 1.926 <0.001* 95.33 (17.45) 89.31 (18.09) 1.204 <0.001* 0.340 0.001*
Superior (mm) 114.22 (21.72) 103.04 (20.80) 2.236 <0.001* 116.44 (22.43) 107.02 (21.95) 1.884 <0.001* 0.546 0.006*
Nasal (mm) 74.01 (17.60) 67.69 (15.18) 1.264 <0.001* 74.87 (18.04) 69.84 (15.28) 1.006 <0.001* 0.405 0.005*
Inferior (mm) 117.20 (22.77) 110.55 (24.14) 1.330 <0.001* 121.11 (25.23) 112.76 (25.34) 1.670 <0.001* 0.306 0.007*
Temporal (mm) 61.88 (21.54) 51.43 (18.75) 2.090 <0.001* 66.04 (19.01) 56.30 (18.01) 1.948 <0.001* 0.388 <0.001*
Macular volume (mm3) 6.53 (0.33) 6.40 (0.30) 0.026 0.002* 6.57 (0.34) 6.45 (0.30) 0.024 0.003* 0.243 <0.001*
SLP
NFI 26.33 (7.83) 26.58 (7.44) 0.005 0.220 24.87 (8.86) 25.02 (8.48) 0.030 0.438 0.549 0.331
TSNIT average (mm) 49.47 (10.67) 49.07 (11.29) 0.080 0.060 52.76 (10.21) 50.91 (11.41) 0.370 0.039 0.600 0.759
Superior average (mm) 60.51 (12.76) 60.93 (11.59) 0.084 0.138 64.33 (11.99) 64.02 (11.56) 0.062 0.238 0.547 0.856
Inferior average (mm) 57.31 (10.10) 56.87 (11.65) 0.088 0.165 60.57 (9.21) 59.99 (10.99) 0.116 0.550 0.763 0.563
TSNIT SD (mm) 23.54 (12.51) 24.33 (13.56) 0.158 0.039 21.12 (9.85) 22.03 (11.43) 0.182 0.044 0.349 0.346
VEP
Amplitude (mV) 8.54 (3.37) 8.76 (3.90) 0.044 0.302 12.11 (2.22) 11.93 (2.42) 0.036 0.769 0.120 0.231
Latency (ms) 118.96 (12.41) 126.05 (13.16) 1.418 0.034 115.77 (9.75) 122.00 (9.27) 1.246 0.029 0.156 0.016
BCVA ¼ best-corrected visual acuity; MD ¼ mean deviation; NFI ¼ nerve fiber indicator; OCT ¼ optical coherence tomography; SD ¼ standard deviation; RNFL ¼ retinal nerve fiber layer; SLP ¼
scanning laser polarimetry; TSNIT ¼ temporalesuperiorenasaleinferioretemporal; VEP ¼ visual evoked potential.
Data are mean (SD) unless otherwise indicated. P < 0.05 was considered to indicate statistical significance.
*Statistical significance using Bonferroni’s correction for multiple comparisons. All statistical differences in change between 3 groups using analysis of variance showed differences between multiple sclerosis














Figure 2. The mean retinal nerve fiber layer thickness measured by optical coherence tomography (OCT) and scanning laser polarimetry (SLP) and the
mean P100 wave latency in visual evoked potentials (VEPs) in the 3 groups (healthy controls, multiple sclerosis [MS] patients without prior optic
neuritis episode, and MS patients with prior optic neuritis episode) during 5 years of follow-up. Multiple sclerosis patients showed more shrinking of the
retinal nerve fiber layer thicknesses during the follow-up and a greater delay in the P100 wave latency compared with healthy controls, but the changes
were similar between both groups of MS patients (with and without prior optic neuritis episode). ON ¼ optic neuritis; TSNIT ¼
temporalesuperiorenasaleinferioretemporal.
Ophthalmology Volume -, Number -, Month 2017prior optic neuritis episode and with healthy controls. Both groups
of patients exhibited a greater decrease in the RNFL parameters
and greater increase in the VEP latency than healthy controls, but
no differences were detected between eyes with and without prior
optic neuritis (Table 3; Fig 2).
The mean annual change was compared with the change during
the first year of the study in the MS cohort and no differences were
detected. A greater decrease of structural variables revealed by
OCT and SLP and a greater increase of VEP latency in the MS
group during the 5-year follow-up were confirmed using the mean
of eyes with nonoptic neuritis in the MS group (Table 4) to account
for intereye within-patient dependencies.22 All the significant
correlations described above were confirmed using the mean of
eyes with nonoptic neuritis in the MS group.
Discussion
The findings of the present study based on OCT, SLP, and
VEP indicate that quantification of RNFL thinning in
patients with MS over a 5-year period can be used as a
biomarker of disease progression and impaired QOL.
Retinal nerve fiber layer thinning occurs not only in eyes
with a prior episode of optic neuritis, but also in patients
with MS with no history of acute optic neuritis.15,23 Retinal
nerve fiber layer thickness measurements by OCT are
considered a useful indirect marker of the progression of
brain atrophy in patients with MS.2,16,24 Optical coherence
tomography also is used to measure macular volume. The
macula comprises ganglion cell bodies, and thus macular
volume could be a useful indicator of axonal loss resulting
from neuronal degeneration.25
In VEP, the P100 wave latency is highly diagnostic in
patients with MS. An episode of optic neuritis can result in a
delay in the P100 latency, with the delay lasting for years.11
In this study, the P100 latency increased over the 5-year
follow-up because of MS progression and the loss of
visual pathway function in the MS patients. The lack of a
reduction in VEP amplitude despite thinning of the RNFL as6
assessed by OCT may be the result of small signals from the
optic nerve (that may be amplified in the cortex, essentially
obscuring or possibly compensating for small differences in
input). Interestingly, the control group also showed a
nonsignificant increase in the P100 latency, which may be
the result of the variability of the device. Thus, although the
VEP P100 wave latency is useful for monitoring MS
progression, it is less sensitive than the OCT measurements.
In our study, we found a very small decrease in the VEP
amplitude and latency in the healthy controls, which was not
significant, and we consider that the VEP variability
explains the small change during the 5-year follow-up.
Functional parameters did not show a significant change
during the follow-up, suggesting that the RNFL loss detected
by OCT was not severe enough to affect functionality or that
compensatory mechanisms could attenuate the neuro-
degenerating effects and avoid relevant clinical deficits
measured by visual acuity, visual field, or color vision.
This is a prospective study with a 5-year follow up in MS
and healthy controls using OCT, SLP, and VEP. Axonal loss
in the RNFL was demonstrated in both healthy controls and
MS patients, but was greater in the MS patients. Consistent
with previous studies, MS patients with and without a prior
optic neuritis episode in the present study exhibited similar
RNFL thinning.15,23,26,27 These findings indicate that a prior
optic neuritis episode is not a risk factor for higher axonal loss
in the optic nerve. Our results confirmed the findings by
Herrero et al26 of a progressive decrease in RNFL thicknesses
and macular volume by OCT in MS patients compared with
healthy controls. However, Herrero et al found an annual
reduction of 0.152 mm in the RNFL average thickness of
the MS population, whereas we registered a greater
decrease (an annual reduction, 1.642 mm). In the study by
Herrero et al, patients were followed up only for 3 years.
Balk et al27 found that the RNFL decrease is independent
of previous episodes of optic neuritis, which is similar to
our findings.
Table 4. Functional and Structural Parameters Obtained at Baseline and 5-Year Examinations in Multiple Sclerosis Patients Using the Mean of Both Eyes in Nonoptic Neuritis
Eyes and in Healthy Controls and Comparison of the Change in Each Group and between Both Groups (Multiple Sclerosis Patients Using the Mean of Both Eyes per Patient vs.
Healthy Controls)





Change P Value Baseline 5 Years
Annual
Change P Value
BCVA 0.91 (0.20) 0.90 (0.21) 0.002 0.441 0.98 (0.04) 0.99 (0.02) 0.002 0.549 0.236
Ishihara test 18.04 (3.98) 17.91 (3.65) 0.026 0.576 19.40 (2.81) 19.38 (2.74) 0.004 0.699 0.435
Visual field, MD (dB) 3.09 (3.01) 3.12 (3.87) 0.006 0.670 0.31 (1.41) 0.29 (1.31) 0.004 0.105 0.611
OCT RNFL thicknesses
Average (mm) 94.43 (15.91) 86.75 (16.23) 1.536 <0.001* 98.21 (10.50) 95.79 (9.53) 0.484 0.032 0.003*
Superior (mm) 115.93 (21.66) 104.30 (20.09) 2.326 0.001* 122.49 (16.93) 120.27 (14.93) 0.444 0.035 0.007*
Nasal (mm) 74.32 (20.29) 68.07 (18.41) 1.250 0.002 78.50 (21.76) 76.59 (10.70) 0.382 0.044 0.004*
Inferior (mm) 119.59 (21.54) 111.65 (21.55) 1.588 <0.001* 126.10 (18.36) 124.73 (17.94) 0.274 0.075 0.009*
Temporal (mm) 64.49 (20.19) 53.64 (17.76) 2.170 <0.001* 68.14 (9.82) 65.87 (9.56) 0.454 0.028 0.002*
Macular volume (mm3) 6.54 (0.34) 6.43 (0.32) 0.022 <0.001* 8.29 (0.44) 8.23 (0.55) 0.012 0.009* 0.005*
OCT GCL analysis (mm)
Average IPLþGCL 78.47 (3.62) 74.93 (3.70) 0.708 0.003* 83.12 (3.20) 81.56 (3.43) 0.312 0.079 0.007*
Minimum IPLþGCL 79.12 (4.87) 77.54 (3.54) 0.316 0.301 81.23 (3.69) 80.00 (3.11) 0.246 0.106 0.110
Fovea 253.01 (9.43) 249.03 (9.00) 0.796 0.008* 256.12 (7.98) 253.38 (8.21) 0.548 0.014 0.006
Inferior 80.70 (3.11) 78.12 (3.44) 0.516 0.023 82.45 (3.33) 80.66 (2.98) 0.358 0.056 0.309
Inferonasal 83.04 (3.70) 81.11 (4.76) 0.386 0.453 84.54 (4.34) 82.32 (3.45) 0.444 0.035 0.488
Nasal 84.69 (3.35) 80.87 (4.22) 0.764 0.011 85.25 (4.21) 83.22 (3.87) 0.406 0.078 0.680
Superior 80.93 (3.24) 77.50 (4.57) 0.686 0.031 83.21 (3.66) 80.98 (3.27) 0.446 0.028 0.047
Inferotemporal 78.77 (3.64) 74.30 (4.01) 0.894 0.006* 82.02 (3.41) 80.56 (3.70) 0.292 0.230 0.008
Temporal 78.88 (3.37) 74.12 (4.33) 0.952 0.003* 81.11 (3.93) 79.82 (4.11) 0.258 0.177 0.007
SLP
NFI 25.19 (9.18) 25.46 (8.65) 0.054 0.541 18.70 (6.87) 19.04 (7.80) 0.068 0.349 0.854
TSNIT average (mm) 51.85 (9.13) 50.92 (12.40) 0.014 0.904 52.33 (6.01) 52.61 (7.71) 0.056 0.451 0.550
Superior average (mm) 62.16 (10.76) 62.47 (11.61) 0.062 0.332 65.32 (5.98) 64.87 (5.50) 0.090 0.559 0.256
Inferior average (mm) 59.66 (9.67) 59.33 (10.12) 0.066 0.421 65.00 (7.09) 64.76 (6.96) 0.048 0.683 0.587
TSNIT SD (mm) 21.96 (4.88) 23.13 (5.31) 0.234 0.040 20.03 (4.21) 20.61 (4.16) 0.116 0.078 0.101
VEP
Amplitude (mV) 11.19 (2.80) 10.90 (3.44) 0.058 0.412 14.54 (2.67) 14.49 (2.55) 0.010 0.449 0.254
Latency (ms) 117.11 (12.93) 123.43 (12.99) 1.264 0.006* 102.03 (7.49) 101.89 (6.90) 0.028 0.618 0.030
BCVA ¼ best-corrected visual acuity; GCL ¼ ganglion cell layer; IPL ¼ inner plexiform layer; MD ¼ mean deviation; NFI ¼ nerve fiber indicator; OCT ¼ optical coherence tomography; RNFL ¼ retinal
nerve fiber layer; SD ¼ standard deviation; SLP ¼ scanning laser polarimetry; TSNIT ¼ temporalesuperiorenasaleinferioretemporal; VEP ¼ visual evoked potential.
Data are mean (SD) unless otherwise indicated. P < 0.05 was considered to indicate statistical significance.














Ophthalmology Volume -, Number -, Month 2017Although we detected no significant correlation between
the changes in SLP parameters and MS progression, the
potential ability of SLP to identify changes in axonal
cytoskeletal processes before neuronal loss and peripapillary
RNFL axon bundles has been described by other authors.28
We found an association between changes in SLP and OCT
in our study, and thus it may be that increasing the sample
size would demonstrate that SLP changes correlate with
disease progression.
Recent studies demonstrate the usefulness of monitoring
peripapillary RNFL thickness by OCT for predicting the
likelihood of increased disability in MS patients over time17
and for predicting a decrease in the quality of life.21 Our
findings are in accordance with these previous reports,
because we found an association between RNFL thinning
and an increased EDSS score (RNFL reduction in the
temporal sector or average thicknesses was associated with
higher disability in these patients) and between a decrease
in the temporal RNFL sector and a decrease in the
MSQOL-54 score (patients with higher temporal RNFL
sector thinning show impaired QOL).
In addition, our study demonstrates an association be-
tween decreases in the fovea, temporal, and inferotemporal
measurements of the GCL provided by OCT and an increase
in the EDSS score over 5 years. As recent studies suggest,
changes in GCL are even more appropriate markers of
clinical neurodegeneration in the visual pathway.29,30
Each eye was analyzed separately in this study because
the eyes can be affected differentially, especially in patients
with unilateral episodes of optic neuritis. Moreover, OCT
devices compare the 3-dimensional profile of the RNFL
thickness of each eye to a normative database. Finally, in
MS patients, a reduction in the macular volume correlates
with neuronal necrosis, demyelination, and axonal dam-
age.21 The loss of ganglion cells also leads to a reduction of
the macular volume (independently in each eye).2,6,31e33
However, some authors consider the inclusion of only
1 eye of each patient adequate for statistical analysis
because RNFL measurements correlate significantly
between the 2 eyes. In our study, we reanalyzed the data
using the mean of eyes with nonoptic neuritis in the MS
group (Table 4) to account for intereye within-patient
dependencies, as recommended by the International Multi-
ple Sclerosis Visual consortium,22 and the results of this
analysis confirmed the progressive axonal loss in MS
patients compared with healthy controls, and the
correlation between the increase in the EDSS and
temporal and superior RNFL thinning detected by OCT,
and between decreased QOL and temporal RNFL thinning
measured by OCT.
Previous studies indicate that a time lapse of 6 months
after an optic neuritis episode is required to detect retro-
grade degeneration based on measurements made using
digital image analysis techniques.31 Here we excluded
patients with an optic neuritis episode during the
6 months preceding the study, so all participants were
considered to have stable MS. We might have detected
greater differences if we had included patients with active
acute relapsing MS episodes in the analysis. However, we8
excluded these patients because the purpose of the study
was to assess only axonal damage secondary to the
progression of MS. The RNFL changes we observed were
the result of only MS-related chronic neurodegeneration,
and not of the acute heavy axonal loss found in acute
relapsing MS episodes. The change in the evaluated
parameters during the first few years was similar to the
mean annual change, suggesting that progressive RNFL
loss is continuous.
A potential limitation of this study is that our population
mainly comprised a mildly affected relapsing-remitting MS
cohort with low EDSS scores, high rates of no or first-line
therapy, stable clinical disease activity without relapse
within 5 years of observation, and a high mean age and
disease duration at inclusion, because our intention was to
reveal neurodegeneration independently of disease activity,
so RNFL thinning may be higher in an MS cohort with
normal disease activity. This should be kept in mind when
interpreting the clinical findings. In conclusion, OCT mea-
surements of RNFL thickness are useful for detecting axonal
damage in MS patients and can be used to monitor disease
progression and changes in QOL.References
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